Kips Biopharma Appoints Yoon Sang-bae as New CEO... "Expecting Sales Growth"

Kips BioPharma announced on the 8th that it has appointed Yoon Sang-bae, former CEO of Huons, as the new CEO of its pharmaceutical division. With the absorption merger of Korea Global Pharmaceutical (a 100% subsidiary) and the recruitment of a pharmaceutical sales and marketing expert as the head, the company is fully prepared to achieve significant results in the pharmaceutical and bio sectors.

Newly appointed CEO Yoon has built leadership experience through various major domestic and international pharmaceutical companies. He is recognized as an expert in sales and marketing. He graduated from Chung-Ang University College of Pharmacy and its graduate school, and completed an MBA program at KAIST. He has worked at Samsung C&T (Bio Business), GSK Korea, Dong-A ST, and Boryung, and served as CEO of Huons from 2022 until the end of last year.

CEO Yoon is regarded as a leading figure in the industry, particularly knowledgeable in the prescription drug business, having served as head of the respiratory business division at GSK Korea and head of the ethical drugs (ETC) division at Boryung Pharmaceutical. At Huons, he led double-digit annual growth of over 10%, achieving annual sales exceeding 500 billion KRW.

With CEO Yoon’s joining, Kips BioPharma plans to significantly expand its existing line of over 180 prescription drug items and extend its business portfolio into over-the-counter drugs. Under Yoon’s leadership, the company aims to expand its existing sales network, which was concentrated in the Honam and Jeju regions, nationwide, with the goal of more than doubling sales within a short period.

Thus, Kips BioPharma has completed the formation of its management team responsible for the overall pharmaceutical and bio business by swiftly recruiting CEO Yoon Sang-bae, who will oversee domestic pharmaceutical operations, alongside Kim Sung-chul, CEO of the bio division, who is developing core pipelines such as anticancer new drugs and oral drug delivery platforms.

Kips BioPharma plans to focus its capabilities on developing core pipelines, including the anticancer drug candidate “Idetrexed,” which targets folate receptor alpha (FR-α), and oral drug delivery platforms, leveraging its solid cash flow as a foundation.